APOE and atherosclerosis: In fact, propagermanium, a drug used clinically for the treatment of chronic hepatitis in Japan, inhibits C-C chemokine receptor 2 function and reduces macrophage infiltration and atherosclerosis in Apolipoprotein E (ApoE) knockout mice [30].